Jeffery J Nielsen1, Stewart A Low2,3. 1. Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA. nielsej@purdue.edu. 2. Novosteo Inc., West Lafayette, IN, USA. 3. Department of Chemistry, Purdue University, West Lafayette, IN, USA.
Abstract
PURPOSE OF REVIEW: Compared with the current standard of implanting bone anabolics for fracture repair, bone fracture-targeted anabolics would be more effective, less invasive, and less toxic and would allow for control over what phase of fracture healing is being affected. We therefore sought to identify the optimal bone-targeting molecule to allow for systemic administration of therapeutics to bone fractures. RECENT FINDINGS: We found that many bone-targeting molecules exist, but most have been developed for the treatment of bone cancers, osteomyelitis, or osteoporosis. There are a few examples of bone-targeting ligands that have been developed for bone fractures that are selective for the bone fracture over the body and skeleton. Acidic oligopeptides have the ideal half-life, toxicity profile, and selectivity for a bone fracture-targeting ligand and are the most developed and promising of these bone fracture-targeting ligands. However, many other promising ligands have been developed that could be used for bone fractures.
PURPOSE OF REVIEW: Compared with the current standard of implanting bone anabolics for fracture repair, bone fracture-targeted anabolics would be more effective, less invasive, and less toxic and would allow for control over what phase of fracture healing is being affected. We therefore sought to identify the optimal bone-targeting molecule to allow for systemic administration of therapeutics to bone fractures. RECENT FINDINGS: We found that many bone-targeting molecules exist, but most have been developed for the treatment of bone cancers, osteomyelitis, or osteoporosis. There are a few examples of bone-targeting ligands that have been developed for bone fractures that are selective for the bone fracture over the body and skeleton. Acidic oligopeptides have the ideal half-life, toxicity profile, and selectivity for a bone fracture-targeting ligand and are the most developed and promising of these bone fracture-targeting ligands. However, many other promising ligands have been developed that could be used for bone fractures.
Entities:
Keywords:
Acidic oligopeptides; Bisphosphonates; Bone fracture drugs; Bone fracture-targeting; Drug-targeting; Systemic administration
Authors: Jeffry S Nyman; Jesse L Even; Chan-Hee Jo; Erik G Herbert; Matthew R Murry; Gael E Cockrell; Elizabeth C Wahl; R Clay Bunn; Charles K Lumpkin; John L Fowlkes; Kathryn M Thrailkill Journal: Bone Date: 2010-12-23 Impact factor: 4.398
Authors: Fu Chen; Xin-Ming Liu; Kelly C Rice; Xue Li; Fang Yu; Richard A Reinhardt; Kenneth W Bayles; Dong Wang Journal: Antimicrob Agents Chemother Date: 2009-08-24 Impact factor: 5.191
Authors: Zuzana Saidak; Carole Le Henaff; Sofia Azzi; Caroline Marty; Sophie Da Nascimento; Pascal Sonnet; Pierre J Marie Journal: J Biol Chem Date: 2015-01-28 Impact factor: 5.157
Authors: T Sekido; N Sakura; Y Higashi; K Miya; Y Nitta; M Nomura; H Sawanishi; K Morito; Y Masamune; S Kasugai; K Yokogawa; K Miyamoto Journal: J Drug Target Date: 2001-04 Impact factor: 5.121
Authors: Parish P Sedghizadeh; Shuting Sun; Adam F Junka; Eric Richard; Keivan Sadrerafi; Susan Mahabady; Neema Bakhshalian; Natalia Tjokro; Marzenna Bartoszewicz; Monika Oleksy; Patrycja Szymczyk; Mark W Lundy; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino Journal: J Med Chem Date: 2017-02-13 Impact factor: 7.446